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1 urgent invasive or non-invasive reperfusion therapy followed by evidence-based phar- 
MAIN OUTCOME MEASURE(S):
Rate of in-hospital catheterization/percutaneous coronary intervention. RESULTS: the registry contained data on 19 483 patients. intravenous thrombolysis was the main reperfusion therapy. Although the overall rate of in-hospital catheterisation/PCI more than doubled over the study period, while the use of primary PCI only slowly increased from 7.6% in 2006/2007 to 13.6% in 2012/2013. the use of evidence-based oral therapies increased steadily over the years except for ACe-inhibitors and angiotensin-receptor blockers. The adjusted risk ratios (RR) for in-hospital mortality for the four sub-groups have not shown any significant improvement. the 30-day adjusted risk ratios however showed a significant albeit gradual risk reduction (RR 0.773 95% CI 0.679-0.881, P<.001).
CONCLUSION: Adherence to evidence-based treatment in SteMi in Malaysia is still poor especially in terms of the rate of primary PCi. Although there is a general trend toward reduced 30-day mortality, the reduction was only slight over the study period. drastic effort is needed to improve adherence and clinical outcomes.
LIMITATION:
Retrospective registry data with inter-hospital variation.
macotherapy are the mainstay of treatment. However, timely invasive percutaneous coronary intervention (PCi) and the adherence to evidence-based pharmacotherapy are still a huge challenge in developing countries. Our population has a high burden of cardiovas-cular risk factors. 2 Local data shows that around 16% of patients undergoing PCi are younger than the age of 45;
3 the elderly tend to be undertreated both pharmacologically and invasively. 4 improving clinical outcomes is of utmost importance and adherence to guidelinebased treatment is crucial in determining the outcome. 
PATIENTS AND METHODS

Source of data
Anonymised patient data were obtained from the Malaysian nCVd-ACS registry for years 2006 to 2013. the nCVd-ACS registrt is sponsored by the Ministry of Health Malaysia and co-sponsored by the national Heart Association of Malaysia. Selected patients were those diagnosed with St-elevation Mi from 18 participating hospitals across Malaysia. data was collected upon admission and throughout the patient stay using a standardized case report form. A unique national identification number was given to each patient to avoid duplication. Follow-up was done at 30 days through phone calls or when patients came to the clinic review. A cross check with the national death registry was also done to verify mortality status. Records were taken of baseline characteristics and clinical presentation, inhospital treatment, procedural details and clinical outcome. data was then entered into the nCVd-ACS website after verification. The operation of the NCVD-ACS is supported by a comprehensive iCt system to ensure functional efficacy and effectiveness.
Patients were categorized into four groups based on the year of admission (2006 to 
Statistical method and analysis
Continuous variables were expressed as mean and standard deviation and differences between the years were analysed using the t test. Categorical variables were described as numbers (percentages), and differences were analysed using the chi-square test or the Fisher exact test. to avert biases in the estimates and loss of power, missing data for explanatory variables were assumed to be missing at random. in the analysis of inhospital and 30-day all-cause mortalities, all significant variables from a univariate analysis were adjusted to produce a final result for in-hospital and 30-day adjusted risk ratios comparing all sub-groups. A generalized linear model with a log link, binomial distribution, and a robust variance estimator was used to estimate the risk ratios. the risk ratios represent the relative risk for mortality of the patients in year 2006 -2007 compared to the other three groups. Variables that were statistically significantly different (a two-sided P value of less than .05) between the years, that were of clinical importance, and that had sufficient outcomes in the respective subcategories were adjusted for in the model. All analyses were conducted using SPSS statistical software (version 21, iBM SPSS Statistics, uSA).
RESULTS
the patient population was predominantly ethnic Malay (more than 50%) with a strong male dominancy (more than 85%) ( Table 1) . the majority of patients fell into the 41 to 60 year-old age group. the prevalence of Malay ethnics and young patients (<40 years old) trended upward over the study period. Smoking was the most prevalent risk factor followed by hypertension and diabetes mellitus. this pattern remained consistent throughout the years with no clear changes. Among the relevant comorbidities, previous myocardial infarction (Mi) was most common followed by chronic renal disease and cerebrovascular disease. All conventional cardiovascular risk factors and related comorbidities remained stable with no marked changes over the years. A large majority of SteMi patients were in Killip class 1 or 2 on presentation. However, there was a steady increase in Killip 4 (cardiogenic shock) presentations.
intravenous thrombolysis was the main mode of reperfusion therapy throughout the study years ( Table 1) . Table 2 . even though the rate of primary PCi did not drastically change over the study period, we observed a significant increase in in-hospital cardiac catheterisations and PCi (including primacr PCi) over the study period ( Table 5 ).
DISCUSSION
in developed western countries, the adoption of timely coronary reperfusion as well as guideline-based pharmacotherapy over the last decade has correlated with an up to 25% reduction in both in-hospital and postdischarge ACS-related mortality. [6] [7] [8] Although there is an encouraging increase in the rate of in-hospital catheterization/PCI for STEMI patients, we are still behind in terms of the actual primary PCis. in-hospital mortality remained constant throughout these years. the Realising this issue, the Ministry of Health, in conjunction with Ministry of education and national Heart institute, initiated a greater Kuala Lumpur SteMi network in late 2015. this network between government hospitals, academic university hospitals and the national Heart institute refers acute SteMi patients directly to PCi capable centres for primary PCi. the aim is to provide access to primary PCi for all patients with SteMi. the network is still at an early stage of development, and due to limitations in supporting staff and facilities, is only active during office hours. nevertheless we hope to develop this network into a 24-hour service within the next few years.
According to the multinational Global Registry of Acute Coronary Events (GRACE), the use of optimal revascularization and statin use could prevent up to 32% and 10% of death by 6 months, respectively, which clearly demonstrates the additional mortality benefits of pharmacotherapy. Although our cohort shows that rates of aspirin, AdP-antagonist and statin use are all more than 85%, a poor prescribing rate for ACE-I/ARB and beta-blocker persists. Unfortunately, pharmacotherapy costs to patients remains a significant barrier. Hence there is ongoing nationwide effort to increase the availability of generic formulations to ease the cost strain to patients.
Analysis of several other acute coronary syndrome registries around the Asia Pacific region shows some discrepancies. even though local guidelines in Australia and new Zealand are generally comparable to those of western countries [9] [10] [11] [12] [13] [14] [15] there are variabilities in the guidelines in other countries. [16] [17] [18] these registries suggest that there is still much room for improvement. A recent effort was the Asia-Pacific real world evidence on outcome and treatment of ACS (APRICOT) project which assembled leading academic teams from several countries across the Asia Pacific region.
19 the APRICOT working group has recommended a few key strategic steps towards improvement in outcome: longer-term patient surveillance, greater patient education (pain awareness, compliance, primary/secondary prevention), overcoming geographical challenges to pre-hospital and post-discharge care, and adoption of a value-based over cost-based healthcare system. 18 A limitation of the study is that it used retrospective registry data that varies among hospitals.
in conclusion, the standard of in-hospital management of SteMi is still sub-optimal in Malaysia and the mortality rate remains high. the rate of primary PCi as the reperfusion strategy is very low as well. Although iV thrombolysis is still relevant in our clinical setting, it should not continue to be the default reperfusion treatment as it has been shown to be inferior to primary PCI. On-going efforts are now being done to improve SteMi care. the greater KL SteMi network started in late 2015 and we look forward to see how it will improve SteMi care and overall clinical outcomes. treating physicians need to be more aware of the importance of evidence-based pharmacotherapy and more generic based medications need to be introduced to ease the cost burden to our patients.
